NASDAQ:CELC

Celcuity - CELC Stock Forecast, Price & News

$10.05

-0.36 (-3.46%)

(As of 08/16/2022 12:00 AM ET)

Add

Compare

Today's Range: $9.65
▼
$10.44
50-Day Range: $7.17
▼
$10.64
52-Week Range: $4.81
▼
$23.11

Volume: 30,404 shs
Average Volume: 67,667 shs
Market Capitalization: $150.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.00

Celcuity MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 238.3% Upside
$34.00 Price Target
Short Interest: Healthy
2.72% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.28
Based on 10 Articles This Week
Insider Trading: Selling Shares
$8,934 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.29) to ($1.57) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

465th out of 1,124 stocks

Medical Laboratories Industry

14th out of 28 stocks

3.5

Analyst's Opinion

Consensus Rating
Celcuity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.00, Celcuity has a forecasted upside of 238.3% from its current price of $10.05.
Amount of Analyst Coverage
Celcuity has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.72% of the float of Celcuity has been sold short.
Short Interest Ratio / Days to Cover
Celcuity has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Celcuity has recently decreased by 6.36%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Celcuity does not currently pay a dividend.
Dividend Growth
Celcuity does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CELC.

2.4

News and Social Media Coverage

News Sentiment
Celcuity has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Celcuity this week, compared to 2 articles on an average week.
Search Interest
2 people have searched for CELC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,934.00 in company stock.
Percentage Held by Insiders
32.90% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 38.30% of the stock of Celcuity is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Celcuity are expected to decrease in the coming year, from ($1.29) to ($1.57) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Celcuity is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Celcuity is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Celcuity has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Celcuity (NASDAQ:CELC) Stock

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Analyst Upgrades and Downgrades

Separately, Craig Hallum dropped their price target on Celcuity from $30.00 to $20.00 and set a "na" rating for the company in a research note on Tuesday, May 17th.

Celcuity Price Performance

Shares of Celcuity stock opened at $10.41 on Tuesday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 22.37 and a current ratio of 22.37. The stock's fifty day moving average is $9.14 and its 200 day moving average is $8.62. The stock has a market cap of $155.54 million, a P/E ratio of -5.05 and a beta of 1.22. Celcuity has a one year low of $4.81 and a one year high of $23.11.

Celcuity (NASDAQ:CELC - Get Rating) last posted its quarterly earnings results on Monday, May 16th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.02). Sell-side analysts anticipate that Celcuity will post -1.29 earnings per share for the current year.

Receive CELC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.

CELC Stock News Headlines

August 16, 2022 | finance.yahoo.com

What Is The Ownership Structure Like For Celcuity Inc. (NASDAQ:CELC)? - Yahoo Finance

August 15, 2022 | seekingalpha.com

Celcuity Inc. (CELC) CEO Brian Sullivan on Q2 2022 Results - Earnings Call Transcript

August 11, 2022 | benzinga.com

Celcuity: Q2 Earnings Insights - Benzinga

August 11, 2022 | seekingalpha.com

Celcuity GAAP EPS of -$0.55 (NASDAQ:CELC) - Seeking Alpha

August 11, 2022 | finance.yahoo.com

Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 9, 2022 | americanbankingnews.com

Celcuity (CELC) Scheduled to Post Earnings on Thursday

August 4, 2022 | benzinga.com

Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call - Benzinga

August 4, 2022 | finance.yahoo.com

Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call

August 3, 2022 | benzinga.com

Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference - Benzinga

August 3, 2022 | finance.yahoo.com

Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference

July 27, 2022 | seekingalpha.com

Celcuity Inc. (CELC) Stock Price Today, Quote & News - Seeking Alpha

July 20, 2022 | marketwatch.com

Celcuity Up 17% After Hours on Breakthrough Therapy Designation for Cancer Drug

July 20, 2022 | seekingalpha.com

Celcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment

July 20, 2022 | finance.yahoo.com

Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS®(celecoxib 56-mg and tramadol hydrochloride 44mg)CI-V as an Efficacious Alternative for Moderate-to-Severe Acute Pain in Appropriate P - Yahoo Finance

July 18, 2022 | seekingalpha.com

Celcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment - Seeking Alpha

July 18, 2022 | marketwatch.com

Celcuity stock soars after hours on breakthrough therapy designation for cancer drug - MarketWatch

July 18, 2022 | finance.yahoo.com

Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer

July 18, 2022 | finance.yahoo.com

Celcuity stock soars after hours on breakthrough therapy designation for cancer drug

July 18, 2022 | streetinsider.com

Celcuity (CELC) Granted FDA Breakthrough Therapy Designation for Gedatolisib - StreetInsider.com

July 18, 2022 | streetinsider.com

Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer - StreetInsider.com

June 15, 2022 | nasdaq.com

Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet - Nasdaq

June 15, 2022 | finance.yahoo.com

Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet

May 31, 2022 | nasdaq.com

Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect? - Nasdaq

May 30, 2022 | finance.yahoo.com

Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect?

May 28, 2022 | finance.yahoo.com

Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences - Yahoo Finance

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CELC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.

CELC Company Calendar

Last Earnings: 11/07/2021
Today: 8/16/2022
Next Earnings (Estimated): 11/14/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CELC
CUSIP: N/A
CIK: 1603454
Web: www.celcuity.com
Phone: (763) 392-0767
Fax: N/A
Employees: 39
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $34.00
High Stock Price Forecast: $48.00
Low Stock Price Forecast: $20.00
Forecasted Upside/Downside: +238.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,600,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -44.95%
Return on Assets: -35.72%

Debt

Debt-to-Equity Ratio: 0.24
Current Ratio: 22.37
Quick Ratio: 22.37

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.61 per share
Price / Book: 2.18

Miscellaneous

Outstanding Shares: 14,941,000
Free Float: 10,025,000
Market Cap: $150.16 million
Optionable: Not Optionable
Beta: 1.22

Key Executives

Mr. Brian F. Sullivan (Age 60)
Co-Founder, Chairman & CEO
Comp: $259.62k
Dr. Lance G. Laing Ph.D. (Age 60)
Co-Founder, Chief Science Officer, VP, Sec. & Director
Comp: $447.92k
Ms. Vicky Hahne (Age 56)
Chief Financial Officer
Comp: $234.52k
Mr. Eric Lindquist
Chief Bus. Officer
Dr. John R. MacDonald Dabt (Age 67)
Ph., Ph.D., Sr. VP of R&D
Ms. Sheri Smith
Acting Head of Clinical Operations
Mr. Igor Gorbatchevsky M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CELC Stock - Frequently Asked Questions

Should I buy or sell Celcuity stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CELC shares.
View CELC analyst ratings or view top-rated stocks.
What is Celcuity's stock price forecast for 2022?: 1 brokers have issued 1 year target prices for Celcuity's stock. Their CELC share price forecasts range from $20.00 to $48.00. On average, they expect the company's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 238.3% from the stock's current price.
View analysts price targets for CELC or view top-rated stocks among Wall Street analysts.
How have CELC shares performed in 2022?: Celcuity's stock was trading at $13.19 at the beginning of 2022. Since then, CELC shares have decreased by 23.8% and is now trading at $10.05.
View the best growth stocks for 2022 here.
When is Celcuity's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our CELC earnings forecast.
How were Celcuity's earnings last quarter?: Celcuity Inc. (NASDAQ:CELC) released its quarterly earnings results on Sunday, November, 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.10. During the same quarter in the prior year, the firm earned ($0.24) earnings per share.
What other stocks do shareholders of Celcuity own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Celcuity investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Evoke Pharma (EVOK), Amicus Therapeutics (FOLD), Allena Pharmaceuticals (ALNA), Ampio Pharmaceuticals (AMPE), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Ovid Therapeutics (OVID).

When did Celcuity IPO?: (CELC) raised $18 million in an initial public offering on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.
What is Celcuity's stock symbol?: Celcuity trades on the NASDAQ under the ticker symbol "CELC."
Who are Celcuity's major shareholders?: Celcuity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.41%), Gagnon Securities LLC (2.07%), Gagnon Advisors LLC (1.21%), Renaissance Technologies LLC (0.57%), Northern Trust Corp (0.27%) and State Street Corp (0.21%).
View institutional ownership trends.
How do I buy shares of Celcuity?: Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Celcuity's stock price today?: One share of CELC stock can currently be purchased for approximately $10.05.
How much money does Celcuity make?: Celcuity (NASDAQ:CELC) has a market capitalization of $150.16 million. The company earns $-29,600,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.
How can I contact Celcuity?: Celcuity's mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The official website for the company is www.celcuity.com. The company can be reached via phone at (763) 392-0767.

This page (NASDAQ:CELC) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Celcuity - CELC Stock Forecast, Price & News

Celcuity MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month